ORKA
Oruka Therapeutics, Inc.
NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY
$68.41
+0.46% today
Updated 2026-04-30
Market cap
$3.42B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.85
Dividend yield
—
52W range
$9 – $91
Volume
1.3M
Oruka Therapeutics, Inc. (ORKA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-59.03M | $-37.06M | $-45.96M | $-18.40M | $-41.73M | $-8.32M | $-6.96M | $-4.08M | $-5.29M | $-9.41M | $-10.53M | $-14.99M | $-17.47M | $-8.24M | $-4.80M | $-7.72M | $-18.76M | $-10.91M | $-57.84M | $-88.21M |
| Capital expenditures | $2.57M | $2.44M | $381000.00 | $1.34M | $185000.00 | $3999.00 | $19000.00 | $0.00 | $32000.00 | $19000.00 | $11000.00 | $12000.00 | $3000.00 | $3999.00 | $4000.00 | $19000.00 | $43000.00 | $2000.00 | $189000.00 | $209000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | $24.24M |
| Free cash flow | $-61.60M | $-39.50M | $-46.34M | $-19.75M | $-41.91M | $-8.33M | $-6.98M | $-4.08M | $-5.32M | $-9.43M | $-10.54M | $-15.00M | $-17.48M | $-8.25M | $-4.80M | $-7.74M | $-18.80M | $-10.91M | $-58.03M | $-88.42M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |